Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 61.6% in February

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 694,600 shares, a decline of 61.6% from the February 13th total of 1,810,000 shares. Based on an average daily trading volume, of 3,830,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.7% of the shares of the stock are short sold.

Institutional Trading of Xilio Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of XLO. Gilead Sciences Inc. acquired a new position in shares of Xilio Therapeutics in the fourth quarter worth $8,696,000. Takeda Pharmaceutical Co. Ltd. purchased a new stake in Xilio Therapeutics during the 4th quarter worth about $1,416,000. Trustees of Columbia University in the City of New York acquired a new position in Xilio Therapeutics in the 4th quarter valued at about $238,000. Geode Capital Management LLC lifted its holdings in Xilio Therapeutics by 85.0% in the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after purchasing an additional 155,337 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its holdings in Xilio Therapeutics by 26.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 343,230 shares of the company’s stock valued at $328,000 after purchasing an additional 70,744 shares in the last quarter. Hedge funds and other institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Price Performance

Shares of XLO stock opened at $0.80 on Friday. The business’s fifty day moving average price is $0.93 and its 200 day moving average price is $0.94. The firm has a market capitalization of $35.18 million, a PE ratio of -0.47 and a beta of -0.38. Xilio Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.93.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.72 million for the quarter, compared to analyst estimates of $2.26 million. Equities research analysts expect that Xilio Therapeutics will post -1.14 earnings per share for the current fiscal year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.